[1] [1] TIEN J C, XU J. Steroid receptor coactivator-3 as a potential molecular target for cancer therapy[J]. Expert Opinion on Therapeutic Targets, 2012, 16(11): 1085-1096.

[2] [2] ZHAO Z, ZHOU S, LI W, et al. AIB1 predicts tumor response to definitive chemoradiotherapy and prognosis in cervical squamous cell carcinoma[J]. Journal of Cancer, 2019, 10(21): 5212-5222.

[3] [3] SAENZ F R , ORY V, SCHMIDT M O, et al. Depletion of the transcriptional coactivator amplified in breast cancer 1 (AIB1) uncovers functionally distinct subpopulations in triple- negative breast cancer[J]. Neoplasia, 2019, 21(10): 963-973.

[4] [4] LI Z, DENG X, WU G, et al. The PI3K and AIB1 interaction is involved in estrogen treated breast cancer cells[J]. Cellular and Molecular Biology, 2018, 64(6): 65-70.

[5] [5] HUANG Y, CEN J, WEI J, et al. Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy[J]. Cancer Biomarkers, 2019, 25(2): 151-160.

[6] [6] SONG X, CHEN H, ZHANG C, et al. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma[J]. Cancer Letters, 2019, 442(1): 310-319.

[7] [7] WANG S M, ZOU Z Z, LUO X Y, et al. LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MD- C1 expression and attenuating DNA damage in human breast cancer[J]. Oncogene, 2018, 37(24): 3243-3259.

[8] [8] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Research, 2017, 45(1): 98-102.

[9] [9] NAGY A, LANCZKY A, MENYHART O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets[J]. Scientific Reports, 2018, 8: 9227.

[10] [10] ZOU Z, YUAN Z, ZHANG Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells[J]. Autophagy, 2012, 8(12): 1798-1810.

[11] [11] ZHANG S, ZHANG Q, SHI G, et al. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target[J]. Biomedecine & Pharmacotherapie, 2018, 97(1): 1189-1194.

[12] [12] PINK R C, BROOKS S A, CARTER D R F. MiRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance[J]. Expert Review of Anticancer Therapy, 2016, 16(1): 57-70.

[13] [13] ZHAI J, SHEN J, XIE G, et al. Cancer-associated fibroblasts- derived IL-8 mediates resistance to cisplatin in human gastric cancer[J]. Cancer Letters, 2019, 454(10): 37-43.

[14] [14] AI Z H, LU Y, QIU S B, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism[J]. Cancer Letters, 2016, 373(1): 36-44.

[15] [15] CHEN P, LUO X, NIE P, et al. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lyso- somal and mitochondrial apoptotic pathway via p53-ROS cross-talk[J]. Free Radical Biology and Medicine, 2017, 104(1): 280-297.

[16] [16] ZOU Z, CHANG H, LI H, et al. Induction of reactive oxygen species: an emerging approach for cancer therapy[J]. Apoptosis, 2017, 22(11): 1321-1335.

[17] [17] ZOU Z, YUAN Z, ZHANG Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells[J]. Autophagy, 2012, 8(12): 1798-1810.

[19] [19] RUDIN C M, YANG Z, SCHUMAKER L M, et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance[J]. Cancer Research, 2003, 63(2): 312-318.